Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-10
2010-02-02
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S283000, C546S268100, C548S255000, C548S373100, C548S579000, C549S429000
Reexamination Certificate
active
07655666
ABSTRACT:
The present invention relates to 1H-Quinazoline-2,4-diones of formula (I)wherein R1and R2are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
REFERENCES:
patent: 6562839 (2003-05-01), Takano et al.
patent: 2003/0153584 (2003-08-01), Weaver et al.
patent: 2007/0208018 (2007-09-01), Allgeier et al.
patent: WO 95/19346 (1995-07-01), None
patent: WO 1996/04288 (1996-02-01), None
patent: WO 97/07799 (1997-03-01), None
patent: WO 98/11892 (1998-03-01), None
patent: WO 98/50036 (1998-11-01), None
patent: WO 2005/030217 (2005-04-01), None
patent: WO 2005/033311 (2005-04-01), None
patent: WO 2006/010591 (2006-02-01), None
Colotta et al., “3-Hydroxy-quinazoline-2,4-dioe as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists”, Bioorg. Med. Chem. Lett., XP-002389894, vol. 14 (2004), pp. 2345-2349.
Ohmori et al., “6-(1H-Imidazol-1-y1)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor”, J. Med. Chem., vol. 37 (1994), pp. 467-475
Takano et al., “Synthesis and AMPA Receptor Antagonistic Activity of a Novel Class of Quinoxalinecarboxylic Acid with a Substituted Phenyl Group at the C-7 Position”, Bioorg. Med. Chem. Lett. vol. 13 (2003), pp. 3521-3525.
Jörg Striessnig, “Pathophysiology of migraine headache: Insight from pharmacology and genetics”, Drug Discovery Today, vol. 2, No. 4 (2005), pp. 453-462.
Catarzi et al., “Synthesis and Biological Evaluation of Analogues of 7-Chloro-4,5-dihydro-4-oxo-8- (1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic Acid (TQX-173) as Novel Selective AMPA Receptor Antagonists”, J. Med. Chem. vol. 47, No. 1 (2004), pp. 262-272.
Novartis AG, Office Action issued in Singapore Patent App. No. 200706385-2, Oct. 5, 2009, 8 pages.
Allgeier Hans
Auberson Yves
Carcache David
Floersheim Philipp
Froestl Wolfgang
Fanelli Strain & Haag PLLC
Novartis AG
Strain Paul D.
Willis Douglas M
Wilson James O
LandOfFree
Substituted 1H-quinazoline-2,4-diones useful as AMPA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1H-quinazoline-2,4-diones useful as AMPA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1H-quinazoline-2,4-diones useful as AMPA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208263